(Q40299423)

19 September 2017

title

Approaches for triaging women who test positive for human papillomavirus in cervical cancer screening (English)

1 reference

19 September 2017

13

1 reference

19 September 2017

Eduardo L Franco

7

0 references

François Coutlée

4

object named as

François Coutlée

1 reference

19 September 2017

6

Alex Ferenczy

1 reference

19 September 2017

10

Marie-Hélène Mayrand

1 reference

19 September 2017

14

Sam Ratnam

1 reference

19 September 2017

5

Máire A Duggan

1 reference

19 September 2017

Michael Fung-Kee-Fung

8

object named as

Michael Fung-Kee-Fung

1 reference

19 September 2017

9

Walter Gotlieb

1 reference

19 September 2017

11

Meg McLachlin

1 reference

19 September 2017

Joseph E Tota

1

1 reference

19 September 2017

James Bentley

2

1 reference

19 September 2017

Jennifer Blake

3

1 reference

19 September 2017

Joan Murphy

12

1 reference

19 September 2017

language of work or name

English

0 references

publication date

6 February 2017

1 reference

19 September 2017

1 reference

19 September 2017

volume

98

1 reference

19 September 2017

page(s)

15-20

1 reference

Performance of ProEx C and PreTect HPV-Proofer E6/E7 mRNA tests in comparison with the hybrid capture 2 HPV DNA test for triaging ASCUS and LSIL cytology

19 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.030

Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.030

Conjunctive p16INK4a testing significantly increases accuracy in diagnosing high-grade cervical intraepithelial neoplasia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.030

The clinical impact of using p16(INK4a) immunochemistry in cervical histopathology and cytology: an update of recent developments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.030

CADM1 and MAL promoter methylation levels in hrHPV-positive cervical scrapes increase proportional to degree and duration of underlying cervical disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.030

Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.030

Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.030

Human papillomavirus DNA methylation as a potential biomarker for cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.030

Projected Impact of HPV and LBC Primary Testing on Rates of Referral for Colposcopy in a Canadian Cervical Cancer Screening Program

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.030

Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.030

The expected impact of HPV vaccination on the accuracy of cervical cancer screening: the need for a paradigm change

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.030

Cost effectiveness of human papillomavirus-16/18 genotyping in cervical cancer screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.030

Screening for cervical cancer precursors with p16/Ki-67 dual-stained cytology: results of the PALMS study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.030

The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.030

The absolute risk of cervical abnormalities in high-risk human papillomavirus-positive, cytologically normal women over a 10-year period

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.030

Semantic focusing allows fully automated single-layer slide scanning of cervical cytology slides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.030

Methylation of viral and host genes and severity of cervical lesions associated with human papillomavirus type 16.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.030

Chromosomal gains measured in cytology samples from women with abnormal cervical cancer screening results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.030

HPV-Testing in Follow-up of Patients Treated for CIN2+ Lesions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.030

Methylation of human papillomavirus type 16 genome and risk of cervical precancer in a Costa Rican population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.030

Practice improvement in cervical screening and management (PICSM): symposium on management of cervical abnormalities in adolescents and young women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.030

Rate of and risks for regression of cervical intraepithelial neoplasia 2 in adolescents and young women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.030

Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.030

Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.030

A randomized controlled trial of Human Papillomavirus (HPV) testing for cervical cancer screening: trial design and preliminary results (HPV FOCAL Trial)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.030

Primary cervical cancer screening with HPV testing compared with liquid-based cytology: results of round 1 of a randomised controlled trial -- the HPV FOCAL Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.030

HPV for cervical cancer screening (HPV FOCAL): Complete Round 1 results of a randomized trial comparing HPV-based primary screening to liquid-based cytology for cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.030

Triaging Pap cytology negative, HPV positive cervical cancer screening results with p16/Ki-67 Dual-stained cytology.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.030

Lower cost strategies for triage of human papillomavirus DNA-positive women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.030

HPV DNA testing with cytology triage in cervical cancer screening: Influence of revealing HPV infection status

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.030

Evaluation of 14 triage strategies for HPV DNA-positive women in population-based cervical screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.030

Effectiveness of cervical screening with age: population based case-control study of prospectively recorded data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.030

The Role of Human Papillomavirus Genotyping in Cervical Cancer Screening: A Large-Scale Evaluation of the cobas HPV Test

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.030

A study of genotyping for management of human papillomavirus-positive, cytology-negative cervical screening results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.030

A cohort study of cervical screening using partial HPV typing and cytology triage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.030

p16/ki-67 dual-stain cytology in the triage of ASCUS and LSIL papanicolaou cytology: results from the European equivocal or mildly abnormal Papanicolaou cytology study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.030

Effectiveness of Cervical Cancer Screening at Different Ages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.030

Introduction of molecular HPV testing as the primary technology in cervical cancer screening: Acting on evidence to change the current paradigm

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.030

Triage by methylation-marker testing versus cytology in women who test HPV-positive on self-collected cervicovaginal specimens (PROHTECT-3): a randomised controlled non-inferiority trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.030

European guidelines for quality assurance in cervical cancer screening. Summary of the supplements on HPV screening and vaccination.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.030

Utility of methylation markers in cervical cancer early detection: appraisal of the state-of-the-science

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.030

Performance of p16/Ki-67 immunostaining to detect cervical cancer precursors in a colposcopy referral population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.030

Methylation of HPV18, HPV31, and HPV45 genomes and cervical intraepithelial neoplasia grade 3.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.030

Interobserver reproducibility and accuracy of p16/Ki-67 dual-stain cytology in cervical cancer screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.030

p16/Ki-67 Dual Stain Cytology for Detection of Cervical Precancer in HPV-Positive Women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.030

Triage of HPV positive women in cervical cancer screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.030

The ATHENA human papillomavirus study: design, methods, and baseline results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.030

Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.030

An evaluation of novel, lower-cost molecular screening tests for human papillomavirus in rural China

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.030

10.1016/J.YPMED.2016.11.030

7 January 2021

Identifiers

DOI

1 reference

19 September 2017

1 reference